CRNX - Crinetics Pharmaceuticals Seeks To Supplant Big Pharma Competition In Acromegaly
Shares of Crinetics Pharmaceuticals (CRNX) have risen by over 40% since its IPO pricing at $17 in July of 2018. Year to date the stock has lost 18% of its value (perhaps due to a lack of news flow).
Given the strong slate of institutional investors involved here and an intriguing pipeline of programs for rare endocrine diseases, I've been looking forward to digging into this one for some time.
Chart
Figure 1: CRNX daily advanced chart (Source: Finviz)
Figure 2: CRNX 15-minute chart (Source: Finviz)
When looking at charts, clarity often comes